Company Overview of EpiCept Corporation
As of August 25, 2013, EpiCept Corporation was acquired by Immune Pharmaceuticals Ltd., in a reverse merger transaction. EpiCept Corporation, a specialty pharmaceutical company, focuses on the clinical development and commercialization of pharmaceutical products for the treatment of pain and cancer. The company develops AmiKet, a prescription topical analgesic cream that has completed Phase II clinical trials for the treatment of peripheral neuropathies. It also develops Azixa, an apoptosis inducer that is in Phase II clinical development for the treatment of brain cancer. In addition, the company is developing crolibulin, a novel small molecule vascular disruption agent and apoptosis induce...
777 Old Saw Mill River Road
Tarrytown, NY 10591
Founded in 1993
Key Executives for EpiCept Corporation
EpiCept Corporation does not have any Key Executives recorded.
EpiCept Corporation Key Developments
EpiCept Corporation(OM:EPCT) dropped from OMX Nordic All-Share Index
Sep 24 13
EpiCept Corporation will be removed from OMX Nordic All-Share Index.
EpiCept Corporation(OM:EPCT) dropped from OMX Nordic Small Cap Index
Sep 24 13
EpiCept Corporation will be removed from OMX Nordic Small Cap Index.
Immune Pharmaceuticals Inc. Announces Management Changes
Aug 26 13
Immune Pharmaceuticals Inc. announced the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation. Immune Pharmaceuticals Inc. also announced that, in connection with the closing of the merger, the composition of the company's board of directors has changed and increased to seven persons. Daniel Teper, the company's Chief Executive Officer, has joined the board of directors as Chairman. David Sidransky, Professor of Oncology at the Johns Hopkins School of Medicine, has been appointed Vice Chairman. Ana Stancic has been named the chairperson of the company's audit committee. Isaac Kobrin, Herve de Kergrohen, and Pierre Albouy have also been named to the company's board. Robert Cook, EpiCept's previous interim President and CEO, retains his position on the board and has become the company's Chief Financial Officer. Alan Dunton, previous non-executive chairman of EpiCept, Robert Savage, and Keith Brownlie have resigned their positions, effective as of the closing date of the merger August 26, 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries